Benefits of Bisphosphonate Therapy: Beyond the Skeleton
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Link
https://link.springer.com/content/pdf/10.1007/s11914-020-00612-4.pdf
Reference76 articles.
1. • Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809. https://doi.org/10.1056/NEJMoa074941Large randomized controlled trial comparing zoledronate to placebo in hip fracture patients. A 28% reduction in mortality was observed in the zoledronate group.
2. • Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1808082Primary analysis of a large clinical trial of zoledronate in postmenopausal women with low bone density; safety analyses demonstrate a signal towards lower mortality, cardiovascular disease, and cancer in zoledronate group.
3. • Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res. 2019. https://doi.org/10.1002/jbmr.3860Prespecified secondary analyses of a large clinical trial of zoledronate in postmenopausal women with low bone density, detailing the effects on mortality, cardiovascular disease, and cancer.
4. Bliuc D, Tran T, van Geel T, Adachi JD, Berger C, van den Bergh J, et al. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporos Int. 2019;30:817–28. https://doi.org/10.1007/s00198-018-4806-0.
5. Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, et al. Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res. 2018;33(8):1422–34. https://doi.org/10.1002/jbmr.3448.
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of Novel Antiosteoporosis Leads with Bone Resorption Inhibition and Anabolic Promotion through a Chemotype-Assembly Approach;Journal of Medicinal Chemistry;2024-08-21
2. CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis;Scientific Reports;2024-07-16
3. Use of an emulated trial to investigate the association between use of nitrogen-based bisphosphonates and risk of epithelial ovarian cancer;International Journal of Epidemiology;2024-06-12
4. The multi-faceted nature of age-associated osteoporosis;Bone Reports;2024-03
5. Effect of Tempeh and Daidzein on Calcium Status, Calcium Transporters, and Bone Metabolism Biomarkers in Ovariectomized Rats;Nutrients;2024-02-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3